Triglycerides Over 3,000: Insulin Drip, Plasmapheresis, or Straight to a Fibrate?
A triglyceride level high enough to cause pancreatitis on its own forces a choice between two clearance strategies with almost no head-to-head trial evidence deciding between them — only what the patient's own trajectory is doing right now.
Bianca V. is twenty weeks pregnant with her second child and arrived in the emergency department with severe epigastric pain her obstetrician initially attributed to round ligament strain before her labs came back. Her triglycerides returned at 3,400 mg/dL — grossly, visibly lipemic serum, milky enough that the lab flagged it before the number itself printed — against a documented baseline of around 400 from bloodwork drawn earlier in this pregnancy, itself already elevated from her pre-pregnancy baseline of roughly 180. Pregnancy's own estrogen-driven rise in triglycerides, layered on an underlying, previously mild lipid disorder she'd never been treated for, produced a level high enough to cause pancreatitis on its own, with no gallstones and no alcohol history to explain it otherwise.
She is not in diabetic ketoacidosis and has no diabetes history, but two hours after arrival her lactate has crept up and her urine output has dropped below what the team wants to see — early, genuine signals of organ involvement, not yet frank organ failure. Insulin infusion activates lipoprotein lipase and reliably lowers triglycerides over hours; plasmapheresis clears them mechanically, faster, but requires specialized apheresis equipment and carries its own procedural risk. Neither option has been tested against the other in an adequately powered randomized trial — what's actually guiding the decision is her own early trajectory, not a settled comparative answer the literature has already provided.
Fetal heart tones have remained normal and reassuring on continuous monitoring since her arrival, a detail the whole team, including her obstetrician, has been checking as often as her own labs — her pregnancy is very much part of this decision, not a background fact to work around. Her husband, waiting just outside the unit with their four-year-old, has asked twice already whether the treatment being considered is safe for the baby, a question the team has answered honestly: both insulin and plasmapheresis are used in pregnancy when clinically indicated, and neither is being chosen or avoided because of the pregnancy itself, only because of what her own numbers are doing.
ICU, within the first two hours
I'd start an insulin infusion now, titrated to a triglyceride-decline target rather than a glucose target. Insulin activates lipoprotein lipase directly, it's immediately available without specialized equipment, and reported reduction rates are comparable to plasmapheresis in most published series — there's no need to reach for the more resource-intensive option first.
Her level and her trajectory both concern me more than "comparable in most series" reassures me. Her lactate is climbing and her urine output is already dropping within the first two hours — early signs of organ involvement, not yet failure, but real. Plasmapheresis clears triglycerides mechanically and faster than insulin's metabolic effect can act, and in a patient trending this direction, the faster-acting option is the more defensible choice even without a randomized trial proving a mortality difference.
Neither of you is wrong about the evidence — that's actually the point worth naming directly: no adequately powered randomized trial has compared these two head-to-head on a hard outcome in this population. Most of what supports either choice is retrospective. Given that honest gap, defaulting to the more available, lower-complication option makes sense as a general rule — unless a specific finding argues for faster clearance.
Her early organ signs are exactly that specific finding. This isn't a case where the tiebreaker is arbitrary — her own trajectory, not just her triglyceride number, is what moves this toward plasmapheresis rather than insulin alone.
Agreed: one session of therapeutic plasma exchange given her early organ signs, with a concurrent low-dose insulin infusion continuing afterward, and fenofibrate planned for once she's tolerating oral intake.
Not agreed: whether a second apheresis session should be pre-scheduled or decided based on the post-session triglyceride level. The critical care physician wants a second session already booked given how high her starting level was; the endocrinologist prefers to let the insulin infusion and one recheck decide whether a second session is actually needed.